Literature DB >> 19776759

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy.

S Mustjoki, P Rohon, K Rapakko, S Jalkanen, P Koskenvesa, T Lundán, K Porkka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19776759     DOI： 10.1038/leu.2009.190

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

Review 1.  Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Authors:  Thomas O'Hare; Matthew S Zabriskie; Anna M Eiring; Michael W Deininger
Journal:  Nat Rev Cancer       Date:  2012-07-24       Impact factor: 60.716

2.  Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy.

Authors:  Xavier Thomas
Journal:  World J Stem Cells       Date:  2012-06-26       Impact factor: 5.326

3.  Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.

Authors:  Jean-Claude Chomel; Marie-Laure Bonnet; Nathalie Sorel; Angelina Bertrand; Marie-Claude Meunier; Serge Fichelson; Michael Melkus; Annelise Bennaceur-Griscelli; François Guilhot; Ali G Turhan
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

4.  Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia model.

Authors:  Gabrielle M Siegers; Tania C Felizardo; A Mark Mathieson; Yoko Kosaka; Xing-Hua Wang; Jeffrey A Medin; Armand Keating
Journal:  PLoS One       Date:  2011-02-03       Impact factor: 3.240

5.  Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.

Authors:  Jean-Claude Chomel; Ali G Turhan
Journal:  Oncotarget       Date:  2011-09

6.  Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

Authors:  Mohamed El Missiry; Henrik Hjorth-Hansen; Johan Richter; Ulla Olson-Strömberg; Leif Stenke; Kimmo Porkka; Anna Kreutzman; Satu Mustjoki
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

Review 7.  Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review.

Authors:  Mohammad Al Hamad
Journal:  F1000Res       Date:  2021-12-15

8.  Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.

Authors:  Lisa Christiansson; Stina Söderlund; Emma Svensson; Satu Mustjoki; Mats Bengtsson; Bengt Simonsson; Ulla Olsson-Strömberg; Angelica S I Loskog
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.